After a single dose, vitamin K2 in the MK-7 form has a plasma half-life of roughly three days, meaning it takes about that long for your blood levels to drop by half. That already makes it unusually persistent compared to other vitamin K forms, but the full picture is more interesting: MK-7 clears from your blood in two phases, and the slower phase can stretch the effective residence time well beyond a week. How fast you absorb it, where it ends up in your body, and what form your supplement takes all influence how long it sticks around and how much work it does while it’s there.
What Happens in the First Few Hours
When you swallow an MK-7 supplement, blood levels start rising within a couple of hours. One study using sensitive mass spectrometry found that MK-7 levels climbed significantly within two to six hours after a dose, then began a gradual decline.1PubMed. Short-term impact of vitamin K2 supplementation on biochemical parameters and lipoprotein fractions That initial spike reflects MK-7 hitching a ride on fat-carrying particles in your blood, the same ones that shuttle dietary triglycerides from your gut to your tissues.
During those first four hours, virtually all vitamin K forms travel in the triglyceride-rich lipoprotein fraction. But MK-7 behaves differently from vitamin K1 after that early window. While K1 stays mostly confined to those initial carriers, MK-7 redistributes into LDL particles as well.2PubMed. Differential lipoprotein transport pathways of K-vitamins in healthy subjects That redistribution is part of why MK-7 lasts so much longer in circulation: it essentially gets repackaged into slower-clearing transport vehicles, giving it more time to reach tissues far from the gut.
The Three-Day Half-Life and Why the Real Answer Is Longer
The most commonly cited figure is a half-life of about 68 hours, or roughly three days. A bioavailability study in healthy volunteers tracked plasma MK-7 out to 72 hours after a single dose and estimated the elimination half-life at about three days, consistent with prior reports of MK-7’s unusually long persistence.3British Journal of Nutrition. The study of bioavailability and endogenous circadian rhythm of menaquinone-7, a form of vitamin K2, in healthy subjects But that number captures only the first, faster phase of clearance.
When researchers tracked MK-7 over a longer washout period of two weeks, they observed a biphasic pattern. In the first phase, the half-life was about three days, matching the usual estimate. But a second, slower phase followed with a half-life stretching to roughly eight days.4Frontiers in Pharmacology. Molecular Pathways and Roles for Vitamin K2-7 as a Health-Beneficial Nutraceutical: Challenges and Opportunities The practical meaning: even after the initial decline, a residual amount of MK-7 lingers in your system for potentially two weeks or more. If you take it daily for a stretch and then stop cold, your body doesn’t run out overnight. Levels taper gradually, with the last traces persisting well beyond what a simple “three-day half-life” implies.
This biphasic behavior is common with fat-soluble vitamins. The fast phase reflects clearance from blood plasma, while the slow phase likely represents MK-7 being released back into circulation from tissue stores. Your bones and arterial walls, in particular, take up MK-7 and presumably release it slowly as those tissues turn over.
Where MK-7 Actually Goes in Your Body
Vitamin K1 and MK-7 have very different destinations. K1, the form found in leafy greens, concentrates heavily in the liver, where it supports the production of clotting factors. MK-7, by contrast, is transported more efficiently to tissues outside the liver, including bones and arterial walls.5BMJ / Open Heart. Vitamin K2—a neglected player in cardiovascular health: a narrative review That’s the key reason MK-7 has attracted so much interest for bone and cardiovascular health: it reaches the places where it’s needed for functions beyond blood clotting.
The LDL-mediated transport pathway plays a role here. Because LDL particles deliver cholesterol to peripheral tissues, MK-7 riding along on those particles gets deposited in bones, blood vessels, and other sites that express LDL receptors. This also means your MK-7 levels in blood don’t tell the whole story of how much is active in your body. Some of it is already sequestered in tissue, doing its job of activating calcium-regulating proteins, even as plasma levels are declining.
How Fat Intake and Food Matrix Affect Absorption
MK-7 is fat-soluble, so it needs dietary fat to be absorbed well. Menaquinones from animal-based foods naturally come packaged with fat, which tends to boost their bioavailability compared to vitamin K1 from plant sources.6British Journal of Nutrition. The role of menaquinones (vitamin K2) in human health If you’re taking MK-7 as a supplement on an empty stomach or with a fat-free meal, you’re likely absorbing less of it than the label dose suggests. Taking it alongside a meal containing some fat, even a modest amount, improves uptake.
Your gut bacteria also produce some vitamin K2, primarily longer-chain forms. There is direct evidence that bacterially synthesized K2 can be absorbed from the lower small intestine, contributing at least partially to your vitamin K status.7PubMed. The contribution of vitamin K2 (menaquinones) produced by the intestinal microflora to human nutritional requirements for vitamin K How much this gut-derived K2 contributes relative to supplements remains an open question, but it means your body isn’t relying solely on dietary intake for its supply.
Genetic Factors That Change How Long MK-7 Sticks Around
Not everyone clears vitamin K at the same rate. One reason is genetic variation in apolipoprotein E, a protein that helps clear vitamin K-carrying lipoprotein remnants from the bloodstream. The three common variants of apoE (E2, E3, and E4) promote this clearance with very different efficiency. The E2 variant clears these remnants fastest, which actually results in lower circulating vitamin K1 levels and a greater sensitivity to anticoagulant drugs. The E4 variant is the slowest, leaving more vitamin K in circulation longer.8The Journal of Nutrition. Transport of Vitamin K to Bone in Humans
While this research focused on K1, the same lipoprotein pathways carry MK-7, so these genetic differences likely influence MK-7 clearance as well. If you carry the E2 variant, your body may pull MK-7 out of circulation and into tissue stores faster, leading to lower plasma levels but not necessarily less biological activity in your bones. If you carry E4, you may maintain higher blood levels for longer. This is one reason two people taking the same supplement dose can show quite different plasma concentrations.
Trans Versus Cis Configuration and Why Supplement Quality Matters
MK-7 exists in two geometric forms: trans and cis. The trans form is the biologically active one. Some synthetic MK-7 products contain a mix of both, and the cis form is dramatically less effective. Research directly comparing the two found that trans MK-7 had a substantially higher ability to activate vitamin K-dependent proteins, while cis MK-7 showed only minimal carboxylation activity, comparable to oxidized trans MK-7 or vitamin K1.9PubMed Central. Carboxylative efficacy of trans and cis MK7 and comparison with other vitamin K isomers
This distinction matters for the “how long does it stay in your system” question because a supplement containing mostly cis MK-7 may show up in blood tests as circulating MK-7 while contributing very little functional vitamin K activity. The molecule is present, but it’s largely inert. If you’re evaluating supplement brands, all-trans MK-7 products are worth seeking out. Fermentation-derived MK-7, typically made using Bacillus subtilis, tends to be predominantly trans, though third-party testing is the only way to verify the ratio for a specific product.
How Long Before MK-7 Produces Measurable Biological Effects
Staying in your system and doing something useful are two different timelines. MK-7’s main biological job is activating proteins that manage calcium, primarily osteocalcin in bone and matrix Gla protein (MGP) in arteries. These proteins need to be carboxylated (a chemical modification that depends on vitamin K) to function properly. Without enough vitamin K, they accumulate in their inactive, undercarboxylated forms.
Supplementation trials show that MK-7 can shift these markers measurably within weeks. In healthy prepubertal children, modest MK-7 supplementation improved osteocalcin carboxylation, reducing the circulating concentration of the inactive form while leaving standard bone markers and clotting parameters unchanged.10PubMed. The effect of menaquinone-7 (vitamin K2) supplementation on osteocalcin carboxylation in healthy prepubertal children In adults, a dose-response study found that daily MK-7 at 100 micrograms or above significantly improved the ratio of active to inactive osteocalcin.11Journal of Nutritional Science and Vitaminology. Low-Dose Daily Intake of Vitamin K2 (Menaquinone-7) Improves Osteocalcin γ-Carboxylation: A Double-Blind, Randomized Controlled Trials
On the vascular side, MK-7 supplementation at 180 micrograms daily reduced levels of inactive MGP by about 31% over 12 weeks, and doubling the dose to 360 micrograms dropped it by about 46%.12PubMed. The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein A randomized trial in patients with aortic valve calcification found that MK-7 combined with vitamin D produced a significant reduction in inactive MGP compared to placebo.13PubMed Central. Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial Placebo-controlled studies in the general population have consistently shown that MK-7 groups experience a roughly 32 to 36% decrease in inactive MGP concentrations while placebo groups stay flat or get worse.14Frontiers in Medicine. Vascular Calcification in Chronic Kidney Disease: The Role of Vitamin K- Dependent Matrix Gla Protein
The takeaway: while a single dose of MK-7 is detectable in your blood for days, the functional payoff from supplementation builds over weeks to months of consistent intake. The three-day half-life tells you about blood-level persistence; the protein-activation data tells you about how long you need to keep taking it before the downstream biology catches up.
The Warfarin Problem
MK-7’s long half-life and accumulation in tissue create a real clinical concern for people taking warfarin or other vitamin K antagonist blood thinners. These drugs work by blocking the vitamin K cycle, so any additional vitamin K in the system works against them. Because MK-7 hangs around for days after each dose and accumulates with repeated use, even small supplemental amounts can destabilize anticoagulation control. Research has shown that daily MK-7 intakes well below common retail supplement doses can produce a clinically meaningful drop in INR (the blood test used to monitor warfarin therapy) and increase the body’s clotting potential. This happens in a dose-dependent fashion, with more MK-7 producing more interference.
This is a sharper problem with MK-7 than with vitamin K1 from food, partly because K1 has a much shorter half-life (measured in hours rather than days) and partly because K1 goes preferentially to the liver, where warfarin’s effects are concentrated, making the interaction somewhat more predictable. MK-7’s broad tissue distribution and slow clearance mean its anticoagulant interference can be both stronger and harder to predict. If you’re on warfarin, even “low dose” MK-7 supplements are something to discuss with whoever manages your anticoagulation, ideally before starting rather than after your INR results come back unexpectedly low.
Safety at Typical and High Doses
For people not on blood thinners, MK-7 has a remarkably clean safety profile. Animal toxicity studies found no adverse effects at doses up to 10 milligrams per kilogram of body weight per day, which provides an enormous margin of safety given that human supplements are dosed in micrograms, typically 25 to 100 micrograms per day.15PubMed Central. Safety and toxicological evaluation of a synthetic vitamin K2, menaquinone-7
No major regulatory body has established a formal tolerable upper intake level for any form of vitamin K, precisely because adverse effects from excess intake have been so hard to find. The UK’s Expert Vitamin and Mineral committee set a guidance level of 1,000 micrograms per day, and the Council for Responsible Nutrition set a supplemental upper intake level of 10,000 micrograms per day, both reflecting how wide the safety margin is.16Scientific Reports. Safety evaluation of vitamin K2 (menaquinone-7) via toxicological tests That said, these figures are for healthy individuals. The warfarin interaction described above is a pharmacological effect, not a toxicity issue per se, but it is the most practically important safety concern associated with MK-7’s long residence time in the body.
Age-Related Differences in Vitamin K2 Levels
Your baseline vitamin K2 status shifts as you age, and this likely affects both how much supplemental MK-7 you need and how your body handles it. In younger adults, circulating levels of longer-chain menaquinones (MK-7 and MK-8) tend to be at least comparable to vitamin K1 levels. In elderly subjects, there is a marked deficit of MK-8, suggesting that either production by gut bacteria declines, absorption worsens, or clearance from the blood accelerates with age. This age-related shift in menaquinone levels is consistent with the broader observation that older adults tend to have poorer vitamin K status overall, which is one reason MK-7 supplementation trials have frequently focused on older populations at risk for osteoporosis or vascular calcification.
The functional consequences of age-related menaquinone deficits show up clearly in the protein-activation data. Older adults tend to have higher levels of undercarboxylated osteocalcin and inactive MGP, suggesting that their vitamin K supply isn’t keeping up with their tissues’ demand. Supplementing with MK-7 can correct those markers, as the trials described above demonstrate, but the correction takes consistent daily intake over weeks. A single course won’t permanently fix the deficit any more than one good meal fixes a long-standing dietary shortfall.
How MK-7 Compares to MK-4 in Staying Power
The contrast with MK-4, the other widely supplemented form of vitamin K2, is stark. MK-4 has a very short plasma half-life and a small area under the curve compared to either K1 or longer-chain menaquinones.17PubMed Central. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women In practical terms, a single dose of MK-4 spikes and vanishes from the blood within hours, while MK-7 from the same meal is still circulating days later. This is why MK-4 is typically dosed at much higher amounts (often 15 to 45 milligrams, or thousands of times the MK-7 dose) to achieve similar functional effects.
The difference comes down to molecular structure. MK-7 has a longer side chain, making it more lipophilic and more readily incorporated into lipoprotein particles for sustained transport. MK-4’s shorter chain gets taken up quickly but also cleared quickly. Both forms activate the same vitamin K-dependent proteins, but MK-7’s staying power means it provides a more sustained supply to extrahepatic tissues like bone and vasculature with a much smaller dose. For someone who forgets a supplement dose occasionally, MK-7’s longer half-life offers a built-in buffer that MK-4 simply doesn’t provide.